Faculty Collaboration Database

Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy. Pediatr Blood Cancer 2008 Mar;50(3):627-9

Date

12/05/2006

Pubmed ID

17143876

DOI

10.1002/pbc.21095

Scopus ID

2-s2.0-38549138337 (requires institutional sign-in at Scopus site)   9 Citations

Abstract

Many patients with hemophilia, particularly those with inhibitory antibodies, utilize central venous access devices (CVADs) to facilitate frequent infusions. Infection of these devices is a common complication of factor replacement therapy. This communication reports our center's experience with CVAD infection in three patients with severe hemophilia A undergoing immune tolerance therapy (ITT) in whom intermittent infusions of recombinant tissue plasminogen activator (rTPA, Cathflo Activase) were utilized. In this small experience, patients experienced a decreased frequency of gram-positive infections when receiving routine rTPA treatments. Larger randomized trial should be performed in this patient population at high risk of CVAD infection.

Author List

Dunn AL, Abshire TC

MESH terms used to index this publication - Major topics in bold

Anti-Bacterial Agents
Bacterial Infections
Catheterization, Central Venous
Child, Preschool
Desensitization, Immunologic
Disease Susceptibility
Drug Evaluation
Factor VIII
Fibrin
Fibrinolysis
Hemophilia A
Humans
Isoantibodies
Recombinant Proteins
Thrombophilia
Tissue Plasminogen Activator